China National Medicines (SHA:600511) posted 2024 net profit attributable to shareholders of 2.00 billion yuan, or 2.6509 yuan per share, down 6.8% from 2.15 billion yuan, or 2.8443 yuan per share, the previous year.
The revenue of the Sinopharm Group (HKG:1099) unit climbed 1.8% year over year to 50.6 billion yuan from 49.7 billion yuan, according to a filing with the Shanghai bourse.
The company declared a cash dividend of 0.80 per share for 2024.
Shares of China National Medicines were down 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.